Your browser doesn't support javascript.
loading
Associations of Serum GDF-15 Levels with Physical Performance, Mobility Disability, Cognition, Cardiovascular Disease, and Mortality in Older Adults.
Webber, Katey; Patel, Sheena; Kizer, Jorge R; Eastell, Richard; Psaty, Bruce M; Newman, Anne B; Cummings, Steven R.
Afiliação
  • Webber K; Research Institute, California Pacific Medical Center, San Francisco, CA.
  • Patel S; Institute on Aging, San Francisco, CA.
  • Kizer JR; Research Institute, California Pacific Medical Center, San Francisco, CA.
  • Eastell R; Cardiology Section, San Francisco Veterans Affairs Health Care System, and Department of Medicine, University of California, San Francisco, San Francisco, CA.
  • Psaty BM; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
  • Newman AB; Department of Oncology and Metabolism, Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK.
  • Cummings SR; Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Heath Systems and Population Health, University of Washington, Seattle, WA.
medRxiv ; 2024 Aug 08.
Article em En | MEDLINE | ID: mdl-39148825
ABSTRACT

Background:

Growth differentiation factor 15 (GDF-15) is a member of the TGFß superfamily secreted by many cell types and found at higher blood concentrations as chronological age increases (1). Given the emergence of GDF-15 as a key protein associated with aging, it is important to understand the multitude of conditions with which circulating GDF-15 is associated.

Methods:

We pooled data from 1,174 randomly selected Health ABC Study (Health ABC) participants and 1,503 Cardiovascular Health Study (CHS) participants to evaluate the risk of various conditions and age-related outcomes across levels of GDF-15. The primary outcomes were (1) risk of mobility disability and falls; (2) impaired cognitive function; (3) and increased risk of cardiovascular disease and total mortality.

Results:

The pooled study cohort had a mean age of 75.4 +/-4.4 years. Using a Bonferroni-corrected threshold, our analyses show that high levels of GDF-15 were associated with a higher risk of severe mobility disability (HR 2.13 [1.64, 2.77]), coronary heart disease (HR 1.47 [1.17, 1.83]), atherosclerotic cardiovascular disease (HR 1.56 [1.22, 1.98]), heart failure (HR 2.09 [1.66, 2.64]), and mortality (HR 1.81 [1.53, 2.15]) when comparing the highest and lowest quartiles. For CHS participants, analysis of extreme quartiles in fully adjusted models revealed a 3.5-fold higher risk of dementia (HR 3.50 [1.97, 6.22]).

Conclusions:

GDF-15 is associated with several age-related outcomes and diseases, including mobility disability, impaired physical and cognitive performance, dementia, cardiovascular disease, and mortality. Each of these findings demonstrates the importance of GDF-15 as a potential biomarker for many aging-related conditions.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article